| CPC A61K 31/4709 (2013.01) [A61K 9/0019 (2013.01); A61P 7/00 (2018.01)] | 29 Claims |
|
1. A method for treating chronic neutropenia, cyclic neutropenia, or congenital neutropenia in a patient in need thereof, wherein the patient does not have a gain-of-function mutation in the CXCR4 gene and has not been diagnosed with WHIM syndrome or with myelokathexis, comprising administering to the patient an effective amount of mavorixafor:
![]() or a pharmaceutically acceptable salt thereof;
wherein the patient has an absolute neutrophil count (ANC) at or below 1,500 cells/μL at a baseline prior to administering mavorixafor or a pharmaceutically acceptable salt thereof; and the amount of mavorixafor or a pharmaceutically acceptable salt thereof administered is 100 mg/day to 600 mg/day.
|